newsfilter
← Latest News
GlobeNewswire·

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry